[68Ga]Ga-FAPI-04 PET/CT或可预测类风湿关节炎早期治疗反应
前瞻性队列研究纳入19例类风湿关节炎患者,探讨基线[68Ga]Ga-FAPI-04 PET/CT能否预测3个月随访时的治疗反应。结果显示,按CDAI和SDAI反应标准,反应者的FAPI-04及FDG PET/CT总滑膜炎摄取和代谢性滑膜炎体积均显著高于非反应者,基线FAPI PET/CT参数高于截断值可区分反应者与非反应者。
要点
- 按CDAI和SDAI标准,3个月随访反应者的FAPI-04与FDG PET/CT总滑膜炎摄取及代谢性滑膜炎体积均显著高于非反应者。
- FAPI-04和FDG PET/CT的PET关节计数在CDAI反应者中显著高于非反应者。
- 基线FAPI PET/CT的PJC、TSU、MSV高于截断值可区分3个月随访的CDAI和SDAI反应者与非反应者。
核心结论
- 基线[68Ga]Ga-FAPI-04摄取在早期反应者中显著高于非反应者。
研究设计与样本
- 前瞻性队列研究最终纳入19例确诊类风湿关节炎的患者。
- 试验注册号ClinicalTrials NCT04514614,注册日期2020年8月13日。
主要发现
- 按CDAI和SDAI反应标准,3个月随访时反应者的[68Ga]Ga-FAPI-04和[18F]FDG PET/CT总滑膜炎摄取及代谢性滑膜炎体积均显著高于非反应者(P < 0.05)。
- CDAI反应者的FAPI-04 PET/CT PET关节计数显著高于非反应者(P = 0.016),FDG PET/CT PET关节计数亦显著高于非反应者(P = 0.045)。
- 基线疾病活动度临床特征在反应者与非反应者间无显著差异,除外CRP(CDAI标准P = 0.035,SDAI标准P = 0.033)。
- 基线[68Ga]Ga-FAPI-04 PET/CT的PJC、TSU和MSV高于截断值可成功区分3个月随访的CDAI和SDAI反应者与非反应者。
关键数值与推荐
- 采用CDAI和SDAI反应标准在3个月随访时判定反应者与非反应者。
- 基线FAPI PET/CT的PJC、TSU、MSV高于截断值可区分CDAI和SDAI反应者与非反应者。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The identification of biomarkers predicting the treatment response of rheumatoid arthritis (RA) is important. [68 Ga]Ga-FAPI-04 showed markedly increased uptake in the joints of patients with RA. The purpose of this study is to investigate whether [68 Ga]Ga-FAPI-04 PET/CT can be a predictor of treatment response in RA. RESULTS: Nineteen patients diagnosed with RA in the prospective cohort study were finally enrolled. Both total synovitis uptake (TSU) and metabolic synovitis volume (MSV) in [68 Ga]Ga-FAPI-04 and [18F]FDG PET/CT of the responders were significantly higher than those in non-responders according to Clinical Disease Activity Index (CDAI) and Simplified Disease Activity Index (SDAI) response criteria at 3-months' follow-up (P < 0.05). The PET joint count (PJC) detected in [68 Ga]Ga-FAPI-04 and [18F]FDG PET/CT were also significantly higher in CDAI responders than non-responders (P = 0.016 and 0.045, respectively). The clinical characteristics of disease activity at baseline did not show significant difference between the responders and non-responders, except CRP (P = 0.035 and 0.033 in CDAI and SDAI response criteria, respectively). The baseline PJCFAPI, TSUFAPI and MSVFAPI > cutoff values in [68 Ga]Ga-FAPI-04 PET/CT successfully discriminated CDAI and SDAI responders and non-responders at 3-months' follow-up. CONCLUSION: [68 Ga]Ga-FAPI-04 uptake at baseline were significantly higher in early responders than those in non-responders. Trial registration ClinicalTrials. NCT04514614. Registered 13 August 2020, https://register. CLINICALTRIALS: gov/prs/app/action/SelectProtocol?sid=S000A4PN&selectaction=Edit&uid=U0001JRW&ts=2&cx=-x9t7cp.
引用
- Pan Q, Yang H, Zhou Z, et al. [68 Ga]Ga-FAPI-04 PET/CT may be a predictor for early treatment response in rheumatoid arthritis. EJNMMI Res. 2024. PMID: 38175339. doi:10.1186/s13550-023-01064-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。